Solid Biosciences' R&D Surge Drives 52% Net Loss Increase

TL;DR

**Solid Biosciences is burning cash fast on R&D, but their recent capital raise gives them a longer runway to hit a clinical home run or strike out.**

AI Summary

Solid Biosciences Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $124.5 million, up from $82.1 million in the same period of 2024. This 51.7% increase was primarily driven by a substantial rise in research and development (R&D) expenses, which climbed to $102.2 million in 2025 from $65.7 million in 2024, reflecting increased investment in its gene therapy pipeline including SGT-003, SGT-212, SGT-501, and SGT-601. General and administrative expenses also rose to $27.6 million from $24.2 million. The company's cash and cash equivalents decreased to $61.4 million at September 30, 2025, from $80.2 million at December 31, 2024, but available-for-sale securities significantly increased to $174.8 million from $68.7 million. Financing activities provided $189.3 million in net cash, largely from public offerings of common stock and pre-funded warrants, which helped bolster total stockholders' equity to $217.9 million from $137.2 million. The company continues to operate at a loss, with an accumulated deficit of $908.0 million as of September 30, 2025, indicating ongoing capital requirements for its drug development programs.

Why It Matters

Solid Biosciences' escalating R&D spend, up 55% year-over-year, signals aggressive advancement of its gene therapy pipeline, particularly for Duchenne muscular dystrophy and Friedreich's ataxia. For investors, this indicates a high-risk, high-reward profile, as clinical trial success could lead to significant market opportunities, while failures could deplete capital. Employees are likely to see continued investment in their programs, but also pressure for results. Customers, specifically patients with rare genetic diseases, stand to benefit from potential new treatments, placing Solid Biosciences in direct competition with other gene therapy developers in these therapeutic areas.

Risk Assessment

Risk Level: high — The company reported a net loss of $124.5 million for the nine months ended September 30, 2025, and an accumulated deficit of $908.0 million, indicating a significant history of losses and reliance on external financing. The substantial increase in R&D expenses to $102.2 million from $65.7 million year-over-year highlights the capital-intensive nature of their drug development, with no current revenue streams to offset these costs.

Analyst Insight

Investors should closely monitor Solid Biosciences' clinical trial progress for SGT-003, SGT-212, and its cardiac candidates, as these are the primary drivers of future value. Given the high burn rate and reliance on public offerings, assess the company's cash runway and potential for further dilution before making investment decisions.

Financial Highlights

net Income

-$124.5M

cash Position

$61.4M

Key Numbers

• $124.5M — Net Loss (Increased from $82.1M in 2024 for the nine months ended September 30, 2025)
• $102.2M — Research and Development Expenses (Increased from $65.7M in 2024 for the nine months ended September 30, 2025)
• $908.0M — Accumulated Deficit (As of September 30, 2025, up from $783.5M at December 31, 2024)
• $61.4M — Cash and Cash Equivalents (As of September 30, 2025, down from $80.2M at December 31, 2024)
• $174.8M — Available-for-Sale Securities (As of September 30, 2025, up from $68.7M at December 31, 2024)
• $189.3M — Net Cash Provided by Financing Activities (For the nine months ended September 30, 2025, primarily from public offerings)
• 77,910,239 — Common Stock Shares Outstanding (As of October 29, 2025)
• $217.9M — Total Stockholders' Equity (As of September 30, 2025, up from $137.2M at December 31, 2024)

Key Players & Entities

• Solid Biosciences Inc. (company) — Registrant in 10-Q filing
• SGT-003 (product) — Gene therapy candidate for Duchenne muscular dystrophy
• SGT-212 (product) — Gene therapy candidate for Friedreich's ataxia
• SGT-501 (product) — Gene therapy candidate for catecholaminergic polymorphic ventricular tachycardia (CPVT)
• SGT-601 (product) — Gene therapy candidate for TNNT2-mediated dilated cardiomyopathy
• Nasdaq Global Select Market (market) — Exchange where SLDB common stock is registered
• SEC (regulator) — Securities and Exchange Commission
• Delaware (company) — State of incorporation for Solid Biosciences Inc.

FAQ

Risk Factors

• Significant Net Loss and Accumulated Deficit [high — financial]: The company reported a net loss of $124.5 million for the nine months ended September 30, 2025, an increase from $82.1 million in the prior year period. This contributes to a substantial accumulated deficit of $908.0 million as of September 30, 2025, indicating a continued need for external financing to fund operations.
• Decreasing Cash and Cash Equivalents [medium — financial]: Cash and cash equivalents decreased to $61.4 million at September 30, 2025, from $80.2 million at December 31, 2024. While available-for-sale securities increased significantly, the reduction in readily available cash could pose short-term liquidity challenges if not managed effectively.
• High Research and Development Expenses [high — operational]: R&D expenses surged to $102.2 million for the nine months ended September 30, 2025, from $65.7 million in the same period of 2024. This substantial increase, driven by pipeline development (SGT-003, SGT-212, SGT-501, SGT-601), while necessary for growth, places significant demand on the company's financial resources.
• Gene Therapy Regulatory Hurdles [high — regulatory]: As a gene therapy company, Solid Biosciences faces stringent regulatory pathways for drug approval. Delays or failures in clinical trials or regulatory reviews for its pipeline candidates could significantly impact future revenue and market access.
• Competition in Gene Therapy [medium — market]: The gene therapy market is highly competitive and rapidly evolving. The success of Solid Biosciences' pipeline will be measured against other companies developing similar or alternative treatments, potentially impacting market share and pricing power.

Industry Context

Solid Biosciences operates in the highly competitive and rapidly advancing gene therapy sector. The industry is characterized by significant R&D investment, long development timelines, and stringent regulatory oversight. Companies are focused on developing novel treatments for rare genetic diseases, with a strong emphasis on clinical trial success and therapeutic efficacy.

Regulatory Implications

As a gene therapy developer, Solid Biosciences is subject to rigorous regulatory scrutiny from bodies like the FDA. Successful navigation of clinical trials and regulatory approval processes is critical. Any delays, setbacks, or adverse findings in these processes pose significant risks to the company's pipeline and future commercialization efforts.

What Investors Should Do

1. Monitor R&D spend and pipeline progression
2. Assess cash burn rate and future financing needs
3. Evaluate the impact of increased available-for-sale securities

Key Dates

• 2025-09-30: End of the third quarter — Reporting period for the 10-Q, showing increased net loss and significant R&D investment.
• 2025-12-31: Previous fiscal year end — Baseline for comparison of cash, equity, and accumulated deficit.

Glossary

Available-for-Sale Securities

Investments that are not classified as held-to-maturity or trading securities. They are reported at fair value, with unrealized gains and losses included in other comprehensive income. (A significant increase in these securities ($174.8M vs $68.7M) indicates a strategic allocation of capital, potentially for future funding needs or investment returns.)

Accumulated Deficit

The cumulative net losses of a company since its inception, less any net gains. It represents the total loss that has not been offset by profits. (The substantial and growing accumulated deficit ($908.0M) highlights the company's long-term investment in R&D and its reliance on external financing.)

Pre-funded Warrants

A type of warrant that allows the holder to purchase a share of common stock at a nominal exercise price, effectively providing immediate ownership of the underlying stock upon exercise. (These were part of the financing activities that provided $189.3 million, indicating a method used to raise capital.)

Year-Over-Year Comparison

Compared to the prior year period, Solid Biosciences has experienced a significant increase in its net loss, rising by 51.7% to $124.5 million for the nine months ended September 30, 2025, primarily due to a substantial 55.6% surge in R&D expenses. While cash and cash equivalents have decreased, the company has successfully raised substantial capital through financing activities, leading to a significant increase in total stockholders' equity. No new material risks were highlighted in the provided text, but the existing risks related to financial performance and R&D execution remain prominent.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share SLDB The Nasdaq

Filing Documents

• sldb-20250930.htm (10-Q) — 3116KB
• sldb-ex31_1.htm (EX-31.1) — 16KB
• sldb-ex31_2.htm (EX-31.2) — 16KB
• sldb-ex32_1.htm (EX-32.1) — 10KB
• sldb-ex32_2.htm (EX-32.2) — 10KB
• img247598877_0.jpg (GRAPHIC) — 1137KB
• 0001193125-25-262818.txt ( ) — 12990KB
• sldb-20250930.xsd (EX-101.SCH) — 1386KB
• sldb-20250930_htm.xml (XML) — 1707KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets at September 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Changes in Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 8 Notes to the Condensed Consolidated Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 30 PART II. OTHER INFORMATION 32 Item 1.

Legal Proceedings

Legal Proceedings 32 Item 1A.

Risk Factors

Risk Factors 32 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 86 Item 5. Other Information 86 Item 6. Exhibits 87

SIGNATURES

SIGNATURES 88 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q includes forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believe," "estimate," "project," "anticipate," "expect," "seek," "predict," "aim," "continue," "possible," "intend," "may," "might," "will," "could," "would" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Quarterly Report on Form 10-Q. We derive many of our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and, of course, it is impossible for us to anticipate all factors that could affect our actual results. All forward-looking statements are based upon information available to us on the date of this Quarterly Report on Form 10-Q. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about: the timing, progress, design and results of ongoing and planned preclinical studies and clinical trials for our neuromuscular (e.g., SGT-003, SGT-212), cardiac (e.g., SGT-401, SGT-501, SGT-601) or other future candidates; our ability to establish or maintain collaborations or strategic relationships; our ability to obtain and maintain U.S. and foreign regulatory approval of our neuromuscular (e.g., SGT-003, SGT-212), cardiac (e.g., SGT-401, SGT-501, SGT-601) or other future candidates, and the timing and scope thereof; the timing and outcomes of regulatory interactions; the size of the patient populations and potential market opport

—FINANCIA L INFORMATION

PART I—FINANCIA L INFORMATION

F inancial Statements (unaudited)

Item 1. F inancial Statements (unaudited) SOLID BIOSCIENCES INC. CONDENSED CONSOLIDA TED BALANCE SHEETS (Unaudited) (in thousands, except share and per share data) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 61,364 $ 80,235 Available-for-sale securities 174,778 68,685 Prepaid expenses and other current assets 8,710 8,382 Total current assets 244,852 157,302 Non-current assets: Operating lease, right-of-use assets 22,535 24,295 Property and equipment, net 4,356 4,747 Other non-current assets 247 366 Restricted cash 1,924 1,952 Total non-current assets 29,062 31,360 Total assets $ 273,914 $ 188,662 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 8,429 $ 4,237 Accrued expenses and other current liabilities 19,050 19,852 Operating lease liabilities 2,032 1,787 Finance lease liabilities 281 1,231 Derivative liabilities 6,550 3,150 Total current liabilities 36,342 30,257 Non-current liabilities: Operating lease liabilities, excluding current portion 19,624 21,159 Total non-current liabilities 19,624 21,159 Total liabilities 55,966 51,416 Commitments and contingencies (Note 10) Stockholders' equity: Preferred stock, $ 0.001 par value — 10,000,000 shares authorized; no shares issued or outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value — 240,000,000 and 120,000,000 shares authorized at September 30, 2025 and December 31, 2024, respectively; 77,882,685 and 40,468,141 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 78 40 Additional paid-in capital 1,125,810 920,609 Accumulated other comprehensive income 48 47 Accumulated deficit ( 907,988 ) ( 783,450 ) Total stockholders' equity 217,948 137,246 Total liabilities and stockholders

View Full Filing

View this 10-Q filing on SEC EDGAR